FDA-cleared profile

Neuro Insight V1.0

Olea Medical S.A.S. · MRI · FDA-cleared (510(k))

Authorized purpose: Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.

Clinical role
MRI post-processing, visualization, and quantitative analysis support
Images and patients
MRI · Brain
Key limitation
Keep in mind: The device does not alter original medical images, is not a standalone diagnostic device, and should not be the sole basis for patient-management decisions; users remain responsible for full-image review and professional judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Multiphase or monophase neurological MR images in DICOM, including FLAIR, T1, T2, T1g, diffusion (DWI), and DSC perfusion series.
  • Who uses it?Intended users: Appropriately trained medical professionals analyzing neurological MRI
  • What does the software produce?Output: Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.
  • What is its most important limitation?Key limitation: The device does not alter original medical images, is not a standalone diagnostic device, and should not be the sole basis for patient-management decisions; users remain responsible for full-image review and professional judgment.

Clinical takeaway. Clinical role: Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.

Evidence takeaway. Evidence from the reviewed source record: The FDA packet describes brain-extraction module validation on 362 manually annotated MR volumes across five-fold cross-validation; this is a submodule evaluation, not an end-to-end clinical outcome study of Neuro Insight.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
MRI post-processing, visualization, and quantitative analysis support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Multiphase or monophase neurological MR images in DICOM, including FLAIR, T1, T2, T1g, diffusion (DWI), and DSC perfusion series.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Intended for use in a clinical/hospital environment by trained professionals, assisting their analysis workflow on neurological MRI images.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Both Neuro Insight V1.0 and Olea Sphere® V3.0 are user-defined software analysis tools used for the analysis of magnetic resonance imaging (MRI) studies. Both devices are intended for use in Clinical/Hospital Environment, by any trained professional." … "It is intended to assist appropriately trained medical professionals in their analysis workflow on neurological MRI images.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Appropriately trained medical professionals analyzing neurological MRI
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The device does not alter original medical images, is not a standalone diagnostic device, and should not be the sole basis for patient-management decisions; users remain responsible for full-image review and professional judgment.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
The FDA packet describes brain-extraction module validation on 362 manually annotated MR volumes across five-fold cross-validation; this is a submodule evaluation, not an end-to-end clinical outcome study of Neuro Insight.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA packet describes brain-extraction module validation on 362 manually annotated MR volumes across five-fold cross-validation; this is a submodule evaluation, not an end-to-end clinical outcome study of Neuro Insight.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Brain-extraction Dice

0.97 Dice

  • EndpointBrain-extraction segmentation overlap
  • Population362 manually annotated neurological MR volumes
  • Tested versionNeuro Insight V1.0 brain-extraction module described in K243681; build not stated

Neuro Insight V1.0 brain-extraction module validation

  • DesignFive-fold cross-validation on manually annotated MR volumes
  • Population362 neurological MR volumes from GE, Siemens, Philips, and Canon systems at 1.5T and 3T
  • Scopeexact submission
  • Tested versionNeuro Insight V1.0 brain-extraction module described in K243681; build not stated
  • Samplen=362
  • IndependenceSponsor or vendor study

K243681

This metric is limited to a brain-extraction subcomponent and should not be read as end-to-end product diagnostic performance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Multiphase or monophase neurological MR images in DICOM, including FLAIR, T1, T2, T1g, diffusion (DWI), and DSC perfusion series.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0

  2. Routing

    Source context, not route validation: NeuroPro can be integrated and deployed through a technical integration environment responsible for transferring, storing, converting, and displaying DICOM data; Neuro Synchronizer can be integrated with compatible environments.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0

  5. Viewer/worklist/report

    Unresolved route: Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
NeuroPro can be integrated and deployed through a technical integration environment responsible for transferring, storing, converting, and displaying DICOM data; Neuro Synchronizer can be integrated with compatible environments.
  • Exact FDA submission
  • Checked 2026-09-06

DICOM integration environment

The exact submission describes NeuroPro integration with an environment that transfers, stores, converts, and displays DICOM imaging data, with optional Neuro Synchronizer viewing and parameter editing.

exact submission · checked 2026-09-06

Web-based MRI workflow

Olea's official Neuro INSIGHT page describes web-based access without installation on the reading station and standard PACS/RIS integrations; the current deployed configuration and exact submission build require confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243681
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Olea Medical Neuro Insight reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    No scoped current security, data-flow, access-control, retention, or incident-response documentation was established.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K243681: Neuro Insight V1.0

    U.S. Food and Drug Administration - Published 2025-07-23 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Neuro Insight V1.0 model card (K243681)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Neuro INSIGHT official product page

    Olea Medical - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

Research history

  1. K243681 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K253489

Swoop® Portable MR Imaging® System

Hyperfine, Inc.

Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.

Modality
MRI
Anatomy
Brain
Decision
2025-12-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history